An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old

Conditions

• β-thalassemia Major

Interventions

• DRUG: Deferasirox

Sponsor

Novartis Pharmaceuticals